Bush Administration Nominates von Eschenbach to Head FDA - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bush Administration Nominates von Eschenbach to Head FDA


ePT--the Electronic Newsletter of Pharmaceutical Technology

Bush Administration Nominates von Eschenbach to head FDA

The Ides of March brought good news to US Food and Drug Administration (Rockville, MD, www.fda.gov) Acting Commissioner Andrew von Eschenbach. The White House announced his nomination to the job on a permanent basis. Von Eschenbach has been the acting head of FDA since former commissioner Lester Crawford resigned in September 2005. As acting head, von Eschenbach’s decision to keep his job as chief of the National Cancer Institute has raised criticism and conflict-of-interest concerns; if confirmed he will have to drop his other hat.

Although he has strong support from pharma and other industries regulated by FDA, von Eschenbach will face a tough confirmation process in the Senate. FDA’s delayed action on approving an OTC version of the morning-after pill Plan B once again is likely to dominate the discussion, along with safety concerns about drugs and medical devices.
White House staffers evidently interviewed a number of outside candidates, but had difficulty finding someone with equally strong medical and research credentials who is familiar with FDA regulatory issues and meets administration political criteria. Everyone agrees that FDA needs a permanent leader, but getting there will not be that easy. 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here